Gut and digestion
Intestinal barrier concerns and “leaky gut” claims
Intestinal permeability is a real research concept, but “leaky gut” is often used as a catch-all explanation for unrelated symptoms. A diagnosis cannot be made from that phrase.
Potential benefits explored
Improved intestinal barrier function.
Larazotide has selected coeliac research, while KPV offers an inflammation-related laboratory rationale. The appeal is a healthier barrier, but that phrase needs a measurable clinical meaning.
Practical interpretation
Test plausible causes such as coeliac disease before unnecessary diet restriction, and treat confirmed disease. Larazotide research did not replace a gluten-free diet.
Meaningful outcomes: Diagnosis-specific symptoms and validated measures where available.
Compare the compounds studied for Intestinal barrier concerns and “leaky gut” claims
Members see the full evidence picture for this condition: every compound studied, graded per condition from strong human evidence through to preclinical-only and negative findings, with human and animal results, risks, combination evidence and cited sources — plus how each compound maps to the research materials we list, with live pricing and stock.
Research reference for laboratory materials only. Not medical advice and not a recommendation for human use. Research cut-off: 30 September 2026.